Drug Manufacturer Fees to Boost Federal Medical Research Funding
This Act introduces new supplemental payments for large pharmaceutical manufacturers that have achieved billion-dollar sales and entered into legal settlements related to violations. These funds are earmarked to significantly increase federal investment in medical research, focusing on chronic diseases and supporting early-career scientists. Citizens stand to benefit from accelerated medical innovation and the development of better treatments in areas where current therapies are inadequate.
Key points
New Fees: Drug manufacturers with "blockbuster" products (over $1 billion in sales) developed with federal funding, and who have entered into covered legal settlements (over $1 million), must pay supplemental fees.
Research Funding Boost: Collected funds (ranging from 0.75% to 1.5% of net income) will be distributed to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) for priority medical research.
Research Priorities: Funds must support radical innovation, research on chronic and degenerative diseases, conditions with unmet medical needs, and provide grants to support early-career scientists.
Non-Compliance Penalty: Failure by a manufacturer to remit the assessed payment for a covered blockbuster drug will result in the drug being deemed "misbranded" under federal law until the payment is made.
Status:
Expired
Civic Will
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.